Developing Cancer Cures to Save a Generation-Clay Siegall’s Story

There is nothing that has been as menacing to the world of modern medicine as cancer. For several decades now, many research institutes and companies have been looking for cures, therapies and other treatment options that either eliminate cancer or ease the treatment and improve the quality of life of the sufferers. The success has not been much, which is why any news of success in cancer drug approved by the FDA is received very warmly by the medical community. This is precisely the achievement which has been made by Clay Siegall, the Owner and managing director at Seattle Genetics.

The company has been in operation for the past two decades, and so far, they have managed to get a drug approved. The drug is very effective in the treatment of multiple types of lymphomas. The company has already started trading their shares publicly under NASDAQ. The sales that have come from the drug which was approved two years ago are close to a million dollars so far. The company has been selling the drug both locally and internationally. Across the border in Canada, the sales of the drug are performed by a corporation knows as Takeda Pharmaceuticals. Besides Canada, there are 60 other countries where the sales of the drug have been approved.

The team at Seattle Genetics is now working towards another goal, making sure that the other 11 drugs that they are working on get approval from the FDA. To make this move a success, they have recruited new staff to assist the current people in the medical laboratories. The owner of the company, Clay Siegall says that the journey towards getting to the level he has reached was not easy. He confided that there were times that money was a real problem, but he expressed gratitude and a lot of optimism for the future.

He hopes that during this century and if possible within the decade, they will have come up with treatments and therapies to deal with cancer comprehensively. With his level of dedication and drive to succeed, it is easy to tell that Seattle Genetics will achieve much more.

The Leadership of Andrew Rolfe

The Senior Managing Director at Towerbrook Capital Partners, Andrew Rolfe has been making an impact on the business world for quite some time. He has a passion for leadership and understands what it takes to make a business successful. Before his current role he has held a number of prestigious roles including the President of Gap Inc. International,the Chairman & CEO of Pret A Manger, the Chairman & CEO of Pret A Manger, and Chief Executive of Booker Foodservice.

Andrew Rolfe is a graduate of Oxford University. Years later he earned his M.B.A. from the prestigious Harvard Business School. Currently Rolfe works as the chairman of the Ubuntu Education Fund. This group is a South African based non-profit group focused on social welfare and education. Rolfe’s experience is widespread. One of his more prominent roles was with GAP where he worked as the President of their International Division. While at GAP, Rolfe was responsible for creating new growth strategies for the company. Under Rolfe’s leadership, GAP grew nearly 500 store locations in the U.K., France and Japan. Furthermore he was largely responsible for the launch of the popular Banana Republic brand in Japan.

Oustide of the GAP, Rolfe has had leadership roles in a number of well known companies. During his career he has served as Vice President of Operations Europe for PepsiCo Restaurants. He has also provided leadership for more than one thousand KFC and Pizza Hut restaurants across 30 countries. Other notable positions Wolfe has held include Non Executive Director at WH Smith PLC, Director of Booker PLC and Director of True Religion Apparel. Andrew Rolfe has built a very impressive resume throughout his career. He has shown a great ability to serve in leadership roles. He is not afraid of a challenge and usually meets it head on. He is sure to be heard from for many years to come.